← Browse by Condition
Medical Condition

diffuse large b cell lymphoma dlbcl

Total Trials
10
Recruiting Now
10
Trial Phases
Phase 2, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — diffuse large b cell lymphoma dlbcl Clinical Trials

How many clinical trials are currently recruiting for diffuse large b cell lymphoma dlbcl?
ClinicalMetric currently tracks 10 actively recruiting clinical trials for diffuse large b cell lymphoma dlbcl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diffuse large b cell lymphoma dlbcl?
diffuse large b cell lymphoma dlbcl research spans Phase 1 (5 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diffuse large b cell lymphoma dlbcl clinical trial?
Eligibility criteria for diffuse large b cell lymphoma dlbcl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
5
Phase 2
3
Top Sponsors
Nurix Therapeutics, Inc. 3 trials
Vastra Gotaland Region 1 trial
The First Affiliated Hospital with Nanjing Medical University 1 trial
Memorial Sloan Kettering Cancer Center 1 trial
Second Affiliated Hospital, School of Medicine, Zhejiang University 1 trial

Recruiting Clinical Trials

NCT06793410 Phase 2
Recruiting
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Enrollment
100 pts
Location
Sweden
Sponsor
Vastra Gotaland Region
View Trial →
NCT07608978 Phase 2
Recruiting
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Enrollment
35 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06765317 Phase 2
Recruiting
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Enrollment
42 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT06464861 Phase 1
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Enrollment
52 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
View Trial →
NCT05107674 Phase 1
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Enrollment
345 pts
Location
United States, Unite...
Sponsor
Nurix Therapeutics, Inc.
View Trial →
NCT05131022 Phase 1
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Enrollment
572 pts
Location
United States, Franc...
Sponsor
Nurix Therapeutics, Inc.
View Trial →
NCT05934084
Recruiting
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Enrollment
552 pts
Location
Italy
Sponsor
Fondazione Italiana Linfomi - ...
View Trial →
NCT06822829
Recruiting
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Enrollment
50 pts
Location
Italy
Sponsor
Azienda USL Reggio Emilia - IR...
View Trial →
NCT07260812 Phase 1
Recruiting
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Enrollment
18 pts
Location
China
Sponsor
TCRx Therapeutics Co.Ltd
View Trial →
NCT04830137 Phase 1
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Enrollment
248 pts
Location
United States
Sponsor
Nurix Therapeutics, Inc.
View Trial →

Related Conditions

mantle cell lymphoma mcl (3) chronic lymphocytic leukemia cll (2) small lymphocytic lymphoma sll (2) follicular lymphoma fl (2) marginal zone lymphoma mzl (2) waldenstrom macroglobulinemia wm (2) primary central nervous system lymphoma pcnsl (2) recipients of allogeneic stem cell transplantation (1) hpv human papillomavirus associated (1) acute myeloid leukaemia (1) myelodysplastic syndrome (1) high grade b cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology